Newsfeeds - Spark Newswire

2 minute read

Bio-Techne To Acquire Namocell; Terms Not Disclosed

Today, 6:01 AM

Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced it has reached an agreement to

TECH

1 minute read

News

Bio-Techne Announced Milerson 40,000 Unique RNAscope in situ Hybridization Probes, Targeting Any Gene, Any Tissue, Any Species

By Charles Gross

Today, 6:01 AM

Bio-Techne Corporation (NASDAQ: TECH) today announced Advanced Cell Diagnostics (ACD), a brand of Bio-Techne, reached an extraordinary milestone of developing over 40,000 unique RNAscope in situ Hybridization (ISH) probes in over 400 species.

TECH

2 minute read

Bio-Techne Reports Exclusive Supply Deal With Nonagen Bioscience For Nonagen’s Oncuria Bladder Cancer Test, No Terms Disclosed

By Benzinga Newsdesk

Today, 6:01 AM

Techne Corporation (NASDAQ:TECH) and Nonagen Bioscience today announced an agreement for R&D Systems, a Bio-Techne brand, to exclusively manufacture Nonagen Bioscience's Oncuria® bladder cancer

TECH

1 minute read

Bio-Techne Q3 Adj. EPS $2.14 Beats $2.00 Estimate, Sales $290.40M Beat $279.92M Estimate

By Bill Haddad

Today, 6:01 AM

Bio-Techne (NASDAQ:TECH) reported quarterly earnings of $2.14 per share which beat the analyst consensus estimate of $2.00 by 7 percent. This is a 19.55 percent increase over earnings of $1.79 per share from the same

TECH

27 minute read

Earnings Scheduled For May 4, 2022

By Benzinga Insights

Today, 6:01 AM

Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.

ABC

1 minute read

10 Biggest Price Target Changes For Wednesday

By Lisa Levin

Today, 6:01 AM

Keybanc lifted the price target for Alphabet Inc. (NASDAQ: GOOGL) from $3,090 to $3,400. Alphabet shares surged 11% to $3,055.00 in pre-market trading.

CLOV

1 minute read

SVB Leerink Maintains Outperform on Bio-Techne, Raises Price Target to $575

By Benzinga Newsdesk

Today, 6:01 AM

SVB Leerink analyst Puneet Souda maintains Bio-Techne (NASDAQ:TECH) with a Outperform and raises the price target from $530 to $575.

TECH

4 minute read

The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson’s Program

By Shanthi Rexaline

Today, 6:01 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ABBV

1 minute read

Death Cross Looms Over Bio-Techne Investors

By Benzinga Insights

Today, 6:01 AM

If history is any guide, there may be trouble ahead for shares of Bio-Techne (NASDAQ:TECH). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

TECH

3 minute read

M&A
News

Bio-Techne Corporation Announced Agreement for Potential 20% Ownership Investment in Wilson Wolf

By Charles Gross

Today, 6:01 AM

Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced it has entered into an option agreement with Wilson Wolf Corporation.

TECH